A case report of super responder of critical COVID-19 pneumonia

J Med Invest. 2021;68(1.2):192-195. doi: 10.2152/jmi.68.192.

Abstract

This report presents a case of a 74-year-old man who showed dramatic therapeutic response to treatment of coronavirus infectious disease-19 (COVID-19) pneumonia. He reported four-day history of sustained fever and acute progressive dyspnea. He developed severe respiratory failure, underwent urgent endotracheal intubation and showed marked elevation of inflammatory and coagulation markers such as c-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH) and D-dimer. Chest computed tomography (CT) demonstrated diffuse consolidation and ground glass opacity (GGO). We diagnosed critical COVID-19 pneumonia with detailed sick contact history and naso-pharyngeal swab of a reverse-transcriptase-polymerase-chain reaction (RT-PCR) assay testing. He received anti-viral drug, anti-interleukin (IL-6) receptor antagonist and intravenous methylprednisolone. After commencing combined intensive therapy, he showed dramatic improvement of clinical condition, serum biomarkers and radiological findings. Early diagnosis and rapid critical care management may provide meaningful clinical benefit even if severe case. J. Med. Invest. 68 : 192-195, February, 2021.

Keywords: ARDS; COVID-19; PCR; methylprednisolone; tocilizumab.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Amides / administration & dosage
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antiviral Agents / administration & dosage
  • COVID-19 / diagnostic imaging
  • COVID-19 Drug Treatment*
  • Critical Illness
  • Drug Therapy, Combination
  • Glucocorticoids / administration & dosage
  • Humans
  • Lung / diagnostic imaging
  • Male
  • Methylprednisolone / administration & dosage
  • Pneumonia, Viral / diagnostic imaging
  • Pneumonia, Viral / drug therapy*
  • Pyrazines / administration & dosage
  • Receptors, Interleukin-6 / antagonists & inhibitors
  • SARS-CoV-2*
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Amides
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Glucocorticoids
  • IL6R protein, human
  • Pyrazines
  • Receptors, Interleukin-6
  • favipiravir
  • tocilizumab
  • Methylprednisolone